Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate–pulsed Dendritic Cells
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
RATIONALE: Exploiting the immunostimulatory capacities of dendritic cells holds great promise for cancer immunotherapy. Currently, dendritic cell-based immunotherapy is evaluated clinically in a number of malignancies, including melanoma and urogenital and lung cancer, showing variable but promising results. OBJECTIVE: To evaluate if pulsed dendritic cells induce protective immunity against malignant mesothelioma in a mouse model. METHODS: Malignant mesothelioma was induced in mice by intraperitoneal injection of the AB1 mesothelioma cell line, leading to death within 28 days. For immunotherapy, dendritic cells were pulsed overnight either with AB1 tumor cell line lysate, AB1-derived exosomes, or ex vivo AB1 tumor lysate, and injected either before (Days -14 and -7) at the day of (Day 0) or after (Days +1 and +8) tumor implantation. MAIN RESULTS: Mice receiving tumor lysate-pulsed dendritic cells before tumor implantation demonstrated protective antitumor immunity with prolonged survival (> 3 months) and even resisted secondary tumor challenge. Tumor protection was associated with strong tumor-specific cytotoxic T-lymphocyte responses. Adoptive transfer of splenocytes or purified CD8+ T lymphocytes transferred tumor protection to unimmunized mice in vivo. When given after tumor implantation in a therapeutic setting, pulsed dendritic cells prevented mesothelioma outgrowth. With higher tumor load and delayed administration after tumor implantation, dendritic cells were no longer effective. CONCLUSIONS: We demonstrate in this murine model that immunotherapy using pulsed dendritic cells may emerge as a powerful tool to control mesothelioma outgrowth. In the future, immunotherapy using dendritic cells could be used as adjuvant to control local recurrence after multimodality treatment for malignant mesothelioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
André, F., Chaput, N., Schartz, N. E. C., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Hsu, D.-H., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2126 · Cited by 496
Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions
Bard, M. P., Hegmans, J. P., Hemmes, A., Luider, T. M., Willemsen, R., Severijnen, L.-A. A., van Meerbeeck, J. P., Burgers, S. A., Hoogsteden, H. C., & Lambrecht, B. N. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0238oc · Cited by 416
Self-citation
Cited by
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
Role of Exosomes/Microvesicles in the Nervous System and Use in Emerging Therapies
Lai, C. P.-K., & Breakefield, X. O. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00228 · Cited by 315
Veltman, J. D., Lambers, M. E., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G., & Hegmans, J. P. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-464 · Cited by 291
Self-citationImmunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
“Initial DC based approaches in mesothelioma using autologous tumor lysate loaded DCs showed promising long-lasting clinical responses with survival up to 66 months post treatment (108-112).”
BackgroundThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
“Pulsed DCs have shown interesting results in pre-clinical models as they prevented tumour outgrowth [44].”
BackgroundResult
Metadata
- Authors
- Hegmans, J. P. J. J., Hemmes, A., Aerts, J. G., Hoogsteden, H. C., & Lambrecht, B. N.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-15
- Volume
- 171
- Issue
- 10
- Pages
- 1168-1177
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2002819940
- Cited by
- 106
- References
- 3
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate–pulsed Dendritic Cells. https://app.cochat.ai/papers/10.1164/rccm.200501-057oc
- The paper
- Hegmans, J. P. J. J., Hemmes, A., Aerts, J. G., Hoogsteden, H. C., & Lambrecht, B. N. (2005). Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate–pulsed Dendritic Cells. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200501-057oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.